
TY  - JOUR
TI  - Winter Meeting 2012. 201st Scientific Meeting of the Pathological Society of Great Britain & Ireland, 5–6 January
JO  - The Journal of Pathology
JA  - J. Pathol.
VL  - 226
IS  - S1
SN  - 0022-3417
UR  - https://doi.org/10.1002/path.4005
DO  - doi:10.1002/path.4005
SP  - S1
EP  - S34
PY  - 2012
ER  - 

TY  - JOUR
TI  - Posters
JO  - Nephrology
JA  - Nephrology
VL  - 19
IS  - S4
SN  - 1320-5358
UR  - https://doi.org/10.1111/nep.12302
DO  - doi:10.1111/nep.12302
SP  - 58
EP  - 88
PY  - 2014
ER  - 

TY  - JOUR
TI  - Supplementary Abstract
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 103
IS  - S5
SN  - 0007-1323
UR  - https://doi.org/10.1002/bjs.10250
DO  - doi:10.1002/bjs.10250
SP  - 5
EP  - 30
PY  - 2016
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 98
IS  - S3
SN  - 0007-1323
UR  - https://doi.org/10.1002/bjs.7526
DO  - doi:10.1002/bjs.7526
SP  - 80
EP  - 217
PY  - 2011
AB  - Abstract The International Surgical Congress of the Association of Surgeons of Great Britain and Ireland takes place this year in Bournemouth, UK (11?13 May 2011). Copyright ? 2011 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
ER  - 

TY  - JOUR
TI  - Abstracts from the 30th Annual Scientific Meeting of the Transplantation Society of Australia and New Zealand
JO  - Immunology & Cell Biology
JA  - Immunol Cell Biol
VL  - 90
IS  - 8
SN  - 0818-9641
UR  - https://doi.org/10.1038/icb.2012.35
DO  - doi:10.1038/icb.2012.35
SP  - A1
EP  - A38
PY  - 2012
ER  - 

TY  - JOUR
AU  - Richardson, Paul G.
AU  - Mitsiades, Constantine S.
AU  - Laubach, Jacob P.
AU  - Lonial, Sagar
AU  - Chanan-Khan, Asher A.
AU  - Anderson, Kenneth C.
TI  - Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers
JO  - British Journal of Haematology
VL  - 152
IS  - 4
SN  - 0007-1048
UR  - https://doi.org/10.1111/j.1365-2141.2010.08360.x
DO  - doi:10.1111/j.1365-2141.2010.08360.x
SP  - 367
EP  - 379
KW  - cancer
KW  - heat shock protein 90
KW  - myeloma
KW  - peripheral neuropathy
KW  - tanespimycin
PY  - 2011
AB  - Summary Heat shock protein 90 (HSP90) is a molecular chaperone that is induced in response to cellular stress and stabilizes client proteins involved in cell cycle control and proliferative/anti-apoptotic signalling. HSP90 is overexpressed in a range of cancers, and may contribute to tumour cell survival by stabilizing aberrant signalling proteins and by interfering with apoptosis. Tanespimycin, an HSP90 inhibitor, reduces tumour cell survival in vitro. In multiple myeloma (MM), HSP90 inhibition affects multiple client proteins that contribute to tumour cell survival, including the IGF1 receptor and the IL-6 receptor, and elements of the PI3/Akt, STAT3, and MAPK signalling pathways. HSP90 inhibition also abrogates the protective effect of bone marrow stromal cells and inhibits angiogenesis and osteoclastogenesis. Tanespimycin acts synergistically with the proteasome inhibitor bortezomib in MM cells and tumour explants, possibly reducing their ability to resist bortezomib-induced stress to the endoplasmic reticulum. The combination of tanespimycin and bortezomib has demonstrated significant and durable responses with acceptable toxicity in a phase I/II study in patients with relapsed and relapsed/refractory MM. HSP90 inhibition is a promising strategy in MM especially in combination with bortezomib; additional studies will further evaluate optimal dosings of candidate drugs and schedules, as well as confirm efficacy in comparative phase III trials.
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - Histopathology
VL  - 57
IS  - s1
SN  - 0309-0167
UR  - https://doi.org/10.1111/j.1365-2559.2010.03637.x
DO  - doi:10.1111/j.1365-2559.2010.03637.x
SP  - 1
EP  - 270
PY  - 2010
ER  - 

TY  - JOUR
TI  - Cardiff Pathology 2009. Fifth Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain and Ireland. 30 June – 3 July 2009. Hosted by the Department of Pathology, Cardiff University. Abstracts.
JO  - The Journal of Pathology
JA  - J. Pathol.
VL  - 219
IS  - S1
SN  - 0022-3417
UR  - https://doi.org/10.1002/path.2619
DO  - doi:10.1002/path.2619
SP  - S1
EP  - S63
PY  - 2009
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - British Journal of Haematology
JA  - Br J Haematol
VL  - 161
IS  - s1
SN  - 0007-1048
UR  - https://doi.org/10.1111/bjh.12263
DO  - doi:10.1111/bjh.12263
SP  - 1
EP  - 81
PY  - 2013
ER  - 

TY  - JOUR
TI  - Poster Session
JO  - Internal Medicine Journal
VL  - 39
IS  - s2
SN  - 1444-0903
UR  - https://doi.org/10.1111/j.1445-5994.2009.01952.x
DO  - doi:10.1111/j.1445-5994.2009.01952.x
SP  - A52
EP  - A77
PY  - 2009
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Nephrology
VL  - 15
IS  - s3
SN  - 1320-5358
UR  - https://doi.org/10.1111/j.1440-1797.2010.01337.x
DO  - doi:10.1111/j.1440-1797.2010.01337.x
SP  - 62
EP  - 144
PY  - 2010
ER  - 

TY  - JOUR
AU  - Kizilbash, Sarah J.
AU  - Snyder, Jon
AU  - Vock, David M.
AU  - Chavers, Blanche M.
C7  - e13572
TI  - Trends in kidney transplant outcomes in children and young adults with cystinosis
JO  - Pediatric Transplantation
JA  - Pediatr Transplant
VL  - 23
IS  - 8
SN  - 1397-3142
UR  - https://doi.org/10.1111/petr.13572
DO  - doi:10.1111/petr.13572
SP  - e13572
KW  - cystinosis
KW  - graft survival
KW  - kidney transplant
KW  - patient survival
KW  - retransplantation
PY  - 2019
AB  - Abstract Temporal changes in kidney transplant outcomes for cystinosis are unknown. We used the SRTR to identify all kidney transplants performed for cystinosis in patients younger than 31 years between 1987 and 2017. We divided time into three equal eras (1987-1997, 1998-2007, and 2008-2017) to assess changes in outcomes using Cox proportional and linear regression models. We examined 441 transplants in 362 patients. Age at ESRD progressively increased (12.1 vs 13.3 vs 13.4; P = .046). Eras 2 and 3 had lower risk of acute rejection (aHR 2 vs 1:0.45; P < .001) (aHR 3 vs 1:0.26; P < .001) and higher 5-year mean GFR (difference 2 vs 1:9.2 mL/min/1.73 m2; P = .005) (difference 3 vs 1:12.9 mL/min/1.73 m2; P = .002) compared with era 1. Five-year graft survival was similar across eras, but 5-year patient survival was higher for era 2 (aHR: 0.25; P = .01). Seventy-nine patients underwent retransplantation. Five-year patient (94.2% vs 92.5%; P = .57) and graft survival (79.1% vs 74.1%; P = .52) were similar between primary and subsequent transplants. Age at ESRD, acute rejection, GFR at 5 years, and patient survival improved over time. Kidney retransplantation is associated with excellent outcomes in children and young adults with cystinosis.
ER  - 

TY  - JOUR
TI  - Mini Oral Sessions
JO  - Transplant International
VL  - 24
IS  - s2
SN  - 0934-0874
UR  - https://doi.org/10.1111/j.1432-2277.2011.01349.x
DO  - doi:10.1111/j.1432-2277.2011.01349.x
SP  - 105
EP  - 130
PY  - 2011
ER  - 

TY  - JOUR
TI  - The ILTS 20th Annual International Congress
JO  - Liver Transplantation
JA  - Liver Transpl
VL  - 20
IS  - S1
SN  - 1527-6465
UR  - https://doi.org/10.1002/lt.23901
DO  - doi:10.1002/lt.23901
SP  - S1
EP  - S399
PY  - 2014
ER  - 

TY  - JOUR
C7  - e26872
TI  - ABSTRACTS
JO  - Pediatric Blood & Cancer
JA  - Pediatr Blood Cancer
VL  - 64
IS  - S4
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.26872
DO  - doi:10.1002/pbc.26872
SP  - e26872
PY  - 2017
ER  - 

TY  - JOUR
TI  - Poster Session
JO  - The Journal of Dermatology
VL  - 39
IS  - s1
SN  - 0385-2407
UR  - https://doi.org/10.1111/j.1346-8138.2012.01624.x
DO  - doi:10.1111/j.1346-8138.2012.01624.x
SP  - 53
EP  - 280
PY  - 2012
ER  - 

TY  - JOUR
TI  - POSTER ABSTRACTS
JO  - BJU International
VL  - 103
IS  - s4
SN  - 1464-4096
UR  - https://doi.org/10.1111/j.1464-410X.2009.08569.x
DO  - doi:10.1111/j.1464-410X.2009.08569.x
SP  - 12
EP  - 46
PY  - 2009
ER  - 

TY  - JOUR
AU  - McKinlay, J.
AU  - Tyson, E.
AU  - Forni, L. G.
TI  - Renal complications of anaesthesia
JO  - Anaesthesia
JA  - Anaesthesia
VL  - 73
IS  - S1
SN  - 0003-2409
UR  - https://doi.org/10.1111/anae.14144
DO  - doi:10.1111/anae.14144
SP  - 85
EP  - 94
KW  - acute kidney injury (AKI)
KW  - risk factors
KW  - peri-operative management
KW  - nephrotoxins
PY  - 2018
AB  - Summary Peri-operative acute kidney injury is common, accounting for 30?40% of all in-hospital cases of acute kidney injury. It is associated with clinically significant morbidity and mortality even with what was hitherto regarded as relatively trivial increases in serum creatinine, and carries over a 12-fold relative risk of death following major abdominal surgery. Comorbid conditions such as diabetes, hypertension, liver disease and particularly pre-existing chronic kidney disease, as well as the type and urgency of surgery, are major risk factors for the development of postoperative acute kidney injury. As yet, there are no specific treatment options for the injured kidney, although there are several modifiable risk factors of which the anaesthetist should be aware. As well as the avoidance of potential nephrotoxins and appropriate volume balance, optimal anaesthetic management should aim to reduce the risk of postoperative renal complications. This may include careful ventilatory management and blood pressure control, as well as appropriate analgesic strategies. The choice of anaesthetic agent may also influence renal outcomes. Rather than concentrate on the classical management of acute kidney injury, this review focuses on the potential development of acute kidney injury peri-operatively, and the means by which this may be ameliorated.
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - HPB
VL  - 12
IS  - s1
SN  - 1365-182X
UR  - https://doi.org/10.1111/j.1477-2574.2010.00165.x
DO  - doi:10.1111/j.1477-2574.2010.00165.x
SP  - 1
EP  - 468
PY  - 2010
ER  - 

TY  - JOUR
TI  - Accepted Abstracts: 2015 Scientific Symposium of the Hemostasis and Thrombosis Research Society April 16–18, 2015 New Orleans, Louisiana
JO  - Haemophilia
JA  - Haemophilia
VL  - 21
IS  - 3
SN  - 1351-8216
UR  - https://doi.org/10.1111/hae.12679
DO  - doi:10.1111/hae.12679
SP  - e260
EP  - e280
PY  - 2015
ER  - 
